Navigation Links
Simcere Pharmaceutical Group to Announce First Quarter 2012 Financial Results on Wednesday, May 9, 2012
Date:4/24/2012

NANJING, China, April 24, 2012 /PRNewswire-Asia/ -- Simcere Pharmaceutical Group (NYSE: SCR), a leading pharmaceutical company specializing in the development, manufacturing, and marketing of branded generic and proprietary pharmaceuticals in China, today announced that it will report its unaudited financial results for the first quarter ended March 31, 2012 on Wednesday, May 9, 2012, before the market opens in the United States. Simcere's management will host an earnings conference call on the same day at 8 a.m. ET (Wednesday, May 9, at 8 p.m. Beijing/Hong Kong time).

To access the conference call, please dial:International toll:+65.6723.9381United States toll-free:+1.866.519.4004United States toll:+1.718.354.1231China Domestic toll:800.819.0121 China Domestic mobile toll:400.620.8038 Hong Kong toll:+852.2475.0994Please ask to be connected to Q1 2012 Simcere Pharmaceutical Group Earnings Conference Call and provide the following passcode: 73500159.Simcere will also broadcast a live audio webcast of the conference call. The broadcast will be available by visiting the "Investor Relations" section of the company's web site at www.simcere.com.

Following the earnings conference call, an archive of the call will be available by dialing:United States toll-free:+1.866.214.5335United States toll:+1.718.354.1232The passcode for replay participants is 73500159. The telephone replay also will be archived on the "Investor Relations" section of the company's website for seven days following the earnings announcement.

About Simcere Pharmaceutical GroupSimcere Pharmaceutical Group (NYSE: SCR, Simcere) is a leading pharmaceutical company specializing in the development, manufacturing, and marketing of branded and proprietary pharmaceuticals in China. Simcere concentrates its research and development efforts on the treatment of diseases with high incidence and/or mortality rates and for which there is a clear demand for more effective pharmacotherapy such as cancer, strokes, cardiovascular disease, infectious diseases and pain. For more information about Simcere Pharmaceutical Group, please visit www.simcere.com.Investor and Media Contacts: Email: ir@simcere.com In Nanjing:In the United States:Yehong ZhangCindy ZhengPresidentBrunswick GroupSimcere Pharmaceutical GroupTel: 1-212-333-3810Tel: 86-25-8556-6666 ext. 8811In Beijing:In Hong Kong:Yue YuJoseph Lo Chi-LunBrunswick GroupBrunswick GroupTel: 86-10-5960-8Tel: 852-3512-5000   

 

 


'/>"/>

SOURCE Simcere Pharmaceutical Group
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Simcere Pharmaceutical Group Reports Unaudited Fourth Quarter and Full Year 2011 Results
2. Simcere and Bristol-Myers Squibb Enter Innovative Partnership to Develop Cardiovascular Compound
3. Simcere Pharmaceutical Group Reports Preliminary Unaudited Third Quarter 2011 Results
4. Simcere Pharmaceutical Group to Announce Third Quarter 2011 Financial Results on Monday, November 14, 2011
5. Simceres Iremod Receives SFDA New Drug Approval
6. Simceres Branded Generic Formulation Biqi Passes EU-GMP Inspection
7. Simcere Pharmaceutical Group Reports Preliminary Unaudited Second Quarter 2011 Results
8. Simcere Pharmaceutical Group to Announce Second Quarter 2011 Financial Results on Tuesday, August 9, 2011
9. Simcere Pharmaceutical Group Provides Notice of Annual General Meeting
10. Simcere Pharmaceutical Group Filed 2010 Annual Report on Form 20-F
11. Simcere Announces Recent Progress of Qiangkes Registration
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/8/2016)... FALLS, N.J., Dec. 8, 2016 CANTEL MEDICAL CORP. ... income of $18,800,000, or $0.45 per diluted share, on a ... first quarter ended October 31, 2016. This compares with net ... of $153,779,000 for the first quarter ended October 31, 2015. ... first quarter ended October 31, 2016 to $21,323,000, or $0.51 ...
(Date:12/8/2016)... , Dec. 8, 2016   Mederi Therapeutics Inc . has announced regulatory ... Therapy, a non-surgical treatment for chronic gastroesophageal reflux disease (GERD). ... ... and broadcast during the Chinese Congress of Digestive Endoscopy, by Professor Jun Liu, Director ... , , "We are very ...
(Date:12/8/2016)... BEIJING , and SAN DIEGO , ... genomic services and solutions with cutting edge next-generation sequencing and ... biotechnology company; and the Genome Institute of ... (NovogeneAIT) – a new joint venture between Novogene and AITbiotech ... at Biopolis, Singapore .   ...
Breaking Medicine Technology:
(Date:12/7/2016)... Orleans, LA (PRWEB) , ... December 07, 2016 ... ... technique used to treat wrinkles and deep lines by smoothing and tightening the ... minimally invasive techniques out there to address facial aging with very little downtime, ...
(Date:12/7/2016)... ... 2016 , ... It is vital for any lab to secure funding, and ... team at Beckman Coulter has designed Kaluza, templates with advanced analytical tools to streamline ... operate in a GLP (Good Laboratory Practice) fashion. , With features designed to simplify ...
(Date:12/7/2016)... ... ... to blow out his candles on his 14th birthday, Estefano Reano had only one wish: ... Joe DiMaggio Children’s Hospital surprised his family with a phone call that made his wish ... was playing at home, when we got the phone call telling us there was a ...
(Date:12/7/2016)... ... December 07, 2016 , ... One of two inventors from Glen Burnie, ... is painful for her. "This is why the co-inventor and I have designed a ... They then created a prototype of the patent-pending AV-AIR, a device that serves as ...
(Date:12/7/2016)... Honolulu, HI (PRWEB) , ... December 07, 2016 ... ... Dermatology is proud to announce that its fully redesigned website, which launched October ... well as a sleek responsive design and easy-to-navigate layout. Visitors and patients can ...
Breaking Medicine News(10 mins):